Hosts named for the 21st annual EIF Revlon Run/Walk for Women
LOS ANGELES — Revlon, the Entertainment Industry Foundation and Lilly Tartikoff have announced the 21st annual EIF Revlon Run/Walk for Women. Revlon brand ambassador Emma Stone will host the 2014 event in New York on May 3, and Revlon brand ambassador Halle Berry, along with Christina Applegate, will host in Los Angeles on May 10.
Stone will be returning for her third year to host the New York Run/Walk, while Berry is celebrating her eighth year participating in the EIF Revlon Run/Walk and hosting the Los Angeles event with Applegate. The Run/Walk was launched in Los Angeles in 1994 through the combined efforts of Lilly Tartikoff; Ronald O. Perelman, chairman of Revlon; and EIF, with a second event in New York City added shortly after. To date, nearly one million people have participated in the EIF Revlon Run/Walk for Women, and the Run/Walks have distributed more than $70 million to support women’s cancer research, counseling and outreach programs.
Like her co-host, Applegate has participated in the Run/Walk several times. As a breast cancer survivor, she is passionate about inspiring other women to take control of their health and providing critical resources to women contending with or at risk of breast cancer.
"Revlon has been involved with the EIF Revlon Run/Walk since its inception and every year, we are reminded of how important it is to keep up the fight against women’s cancers until we find a cure," Perelman, co-founder of the Run/Walk and co-founder of the Revlon/UCLA Women’s Cancer Research Program, said. "I would like to thank all of the volunteers and city officials who help make our event possible each year."
NACDS stresses community pharmacy commitment to safe U.S. Rx supply chain
ARLINGTON, Va. — In lead-up to a House Panel hearing on Thursday, the National Association of Chain Drug Stores submitted a statement expressing its support for the leadership and efforts of Congress and the Food and Drug Administration in taking common-sense approaches in safeguarding the process of delivering prescription medications to patients.
The hearing is being held by the U.S. House of Representatives Committee on Appropriations Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Subcommittee titled, “Budget Hearing — Food and Drug Administration.”
In its statement, NACDS cited pharmacy’s work to help shape the Drug Quality and Security Act, its ongoing advocacy and engagement in the implementation of the new law, and its long-term efforts to safeguard the drug distribution supply chain.
“Chain pharmacies wholeheartedly support efforts to secure the U.S. drug distribution supply chain. They have invested significant resources and efforts toward this goal over many years, including changes in their purchasing practices, and actively supporting state legislation that strengthened supply chain integrity,” NACDS said in its statement.
NACDS also stressed the need to address the problem of illegitimate Internet drug sellers to help protect U.S. consumers from counterfeit and adulterated medications, and recognized FDA’s efforts to educate consumers and healthcare providers about the risks of illegal online drug sellers.
“We support targeting illegal Internet drug sellers through the chokepoint approach. Under this approach, Internet service entities and companies — such as domain name registrars that issue websites, financial entities that handle payment transactions for online sales, Internet Service Providers that provide information from the Internet and common carriers that provide the mailing services — would have authority to stop illicit transactions at their point of interaction with these bad actors,” NACDS said in its statement.
NACDS also urged Congress and the FDA to provide an Internet portal so that consumers and healthcare providers would have the ability to check if an online website offering to sell medications is legitimate.
In its statement, the association urged Congress to provide the FDA with requisite funding necessary to establish an abbreviated approval pathway for biosimilars and interchangeable versions of biological products.
“For the benefit of the patients we serve, we have urged the agency to make establishing this pathway among its highest priorities. Increasing generic drug utilization is one of the most effective ways to control healthcare costs,” NACDS said in its statement.
“We believe that the U.S. supply chain is one of the safest, if not the safest, in the world. The strength and commitment of chain pharmacies and other U.S. supply chain stakeholders are key components in helping achieve this security,” NACDS said in its statement.
PANTHERx wins exclusive contract for the South Carolina ADAP
PITTSBURGH — PANTHERx Specialty Pharmacy on Thursday announced that it has been awarded the exclusive contract to serve as the specialty pharmacy provider for the South Carolina AIDS Drug Assistance Program Direct Dispensing service tier, effective June 1, 2014.
As an ADAP provider, PANTHERx Specialty will help to facilitate no-cost access to essential medications for low-income, uninsured and under-insured residents of South Carolina, utilizing a combination of state and federal funds. The South Carolina ADAP serves approximately 3,200 enrollees monthly.
"PANTHERx Specialty will initiate outreach to welcome all current ADAP patients and prescribers and to notify them of the transition of services, including how to access the myPANTHERx online portal to help manage refills," saidy Rob Snyder, PANTHERx director operations.